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URETERAL CANCER PRODUCING GRANULOCYTE COLONY-
STIMULATING FACTOR: A CASE REPORT 
Mitsuru KAJIWARA1， Kazuaki MUTAGUCHI1， Mari HANADA1， 
Hiroaki MIZOGUCHI1 and Taisuke OHGUCHI2 
1 The Department of Urology， Nakatsu Daiichi Hospital 
2The Department of Urology， Kobatake Hospital 
A 60-year司oldman who underwent radical nephroureterectomy due to left ureteral cancer 22 
months before (transitional cel carcinoma， pT4pNOMx， grade 2， INF s)， was admitted to the hospital 
with the chief compliant of anorexia and body weight los. The patient had severe leukocytosis and 
elevation of C-reactive protein， with no obvious focus of infection. Abdominal plain computed 
tomographic scan revealed left external ileac lymph node swelling. Positron emlSSlOn tomography 
demonstrated left external ileac lymph node recurrence. Enzyme immunoassay of the serum 
demonstrated a markedly high concentration of granulocyte colony-stimulating factor (G-CSF; 790 
pg/ml). Immunohistochemical examination of ureteral cancer cells with anti-G-CSF monoclonal 
antibody demonstrated G-CSF production in cancer cels. A丘erdiagnosed as lymph node recurrence 
of ureteral cancer producing G・CSF，the patient underwent radiotherapy (total 4，000 Gy). CT after 
radiotherapy showed the complete disappearance of the lymph node swelling. 
To our knowledge， this is the second report ofureteral cancer proven to produce G閏CSFinJapan 
(Hinyokika Kiyo 51: 627-630， 2005) 
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組織学的診断は transitiona!cel carcinoma， 








入院時検査所見:抹消血液検査:RBC 4. 52X 106/ 
μ1， Hg 14.2 g/d!， WBC 10， 800/mm3 (neut. 76%)， 
PLT 2. 2X 105/μ1.血液生化学検査:Cre 2. 3 mg/d!， 
BUN 48 mg/d!， 24 h CCr 37.6 ml/min， CRP 2.4 mg/ 
dl以外特記所見なし.尿検査:尿蛋白(+-)，尿潜







入院後経過:同年 7月23日から CMZ(2 g/day) 
3日間，その後 CFDN(300 mg) 14日間処方.加療
後，尿検査結果は正常化したが，血液検査は WBC
24，280/mm3 (neut. 91 %)， CRP 3.4 mg/d!と増加し
ため，胸腹部単純 CT撮影施行.CT上，左外腸骨リ
ンパ節腫大 (22X18 mm)あり.Positron emlSSlOn 
tomography (PET)による全身検索を患者が希望し，
CT検査3週間後の PETでは，リンパ節は急激に腫
大化し (52X 32 mm)， 18F_FDG異常集積を認めた
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Fig. 1. Positron emission tomography. _demon-
strated the abnormal uptake of 'OF_FDG 
at external ileac Iymph node (52 X 32 mm 
in diameter). 
(Fig. 1). G-CSF産生尿管癌外腸骨リンパ節再発を考
え，血清 G-CSF濃度を測定すると， 790 pg/ml (EIA ; 
参考値 18.1pg/ml以下)， IL-6 32. 2 pg/ml (CLEIA ; 
基準値 4.0pg/ml以下)と異常高値を示した.また，
22カ月前に施行した腎尿管全摘出術時の尿管癌標本を
抗ヒト G-CSFモノクローナル抗体 (DABU niversal 






法施行(計4，000Gy).治療開始前 WBC42， 400/mm3 
(neut. 88%)， CRP 8.2 mg/dlは治療開始後から速や
かに減少し，治療開始後第22日目に WBCは正常関内








Fig. 2. Immunohistochemical1y， most uretera1 
cancer cel1s resected 22 months before 
were positive for anti-G-CSF antibody 
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Fig. 3. Clinical course and sequential changes of WBC， G-CSF and CRP. 
Table 1. Previous reports of renal pelvic and ureteral cancer producing G・CSFin literature 
No. 報告者 発表年年齢 性別 原発部位 組織型 白血球数 G-CSF 治療 予後
吉田 1995 73 male renal pelvic TCC 87，000 1，310 CTx dead 8 M 
2 Morita 1995 85 male ureter SCC 41，300 162 none dead 2 M 
3 小島 1996 60 male renal pelvic TCC>SCC 30， 100 66.3 Ope dead 2 M 
4 山本 1997 61 male renal pelvic TCC 48，400 104 Ope dead 3 M 
5 根笹 1997 82 male renal pelvic TCC>SCC 92，600 39.9 Ope dead 3 M 
6 Kamai 1988 53 male renal pelvic SCC 116，780 220 Ope dead 110 days 
7 資藤 2000 48 female renal pelvic TCC 68，200 152 Ope dead 2 M 
8 Higashi 2001 69 male renal pelvic SCC十SC 90，200 79 none dead 1.5 M 
9 岡田 2002 73 male renal pelvic TCC s/o 121，000 250 CTx dead 2 M 
10 Kitayama 2004 62 male renal pelvic TCC 180，000 296 CTx+RTx dead 4 M 
I 自験例 2004 60 male ureter TCC 40，400 790 RTx alive 
TCC; transitional cel carcinoma， SCC; squamous cel carcinoma， SC; sarcomatous change， CTx; chemotherapy， RTx; 
radiotherapy. 白血球数 (/mm3)， G-CSF 濃度 (pg/mI)• 
1995年 Moritaらが本邦第 l例目の G-CSF産生尿管
癌を報告4)して以来，われわれが集計しえた限りでは



















体)， 2. 血清 G-CSF濃度上昇， 3.加療による抹消
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血白血球数，血清 G-CSF濃度の低下ー 4.抗 G心SF
モノクローナル抗体を用いた免疫染色による癌細胞の
G心SF産生の証明，以上すべてを満たすことが必要
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